Advertisement

The FDA prohibits Hospira from importing any new Symbiq infusion pumps systems after the medical device company recalled the devices over a touchscreen issue.

Hospira logo

Infusion pump maker Hospira (NYSE:HSP) found itself in deepening water after the FDA decided to prohibit the company from importing any new lots of its Symbiq touchscreen-enabled infusion pumps.

The pumps, which are imported from the company's manufacturing facility in Costa Rica, underwent a Class I recall late last month over touchscreen issues that the FDA said may result in delayed or inaccurate medication delivery that could injure patients.

Advertisement
Advertisement